An increased hypoxic microenvironment correlates with higher HIF1A expression and represses the expression of ASS1, a key enzyme associated with therapeutic efficacy of ADI-PEG 20 in HCC, through transcriptional regulation of ASS1 promoter activity (29). Here, ASS1 is linked to hepatocellular carcinoma.